Skip to main content
Top
Published in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie 10/2013

01-10-2013 | Reports of Original Investigations

Analysis of histomorphology in malignant hyperthermia-susceptible patients

Authors: David Orlov, MD, Julia Keith, MD, Derek Rosen, MD, Sidney Croul, MD, Natalia Kraeva, PhD, Sheila Riazi, MD

Published in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie | Issue 10/2013

Login to get access

Abstract

Background

Malignant hyperthermia (MH) is a potentially lethal disorder of skeletal muscle triggered by anesthetic agents. A histomorphological examination of diseased muscle may provide insight into MH pathophysiology, but it is not a routine part of standard-of-care practice for the identification of MH-susceptibility. In this study, we investigated muscle histomorphology in a large cohort of MH-susceptible (MHS) patients and examined its relationship to genotype and phenotype.

Methods

All consenting patients who were identified as MHS based on a caffeine-halothane contracture test (CHCT) performed during 1992-2011 were retrospectively identified and recruited for this study. Results of the histomorphological examination, which is a routine part of our centre-specific practice, were reviewed. Patient demographics, MH proband status, histological features, CHCTs, and genetic results for MH-causative mutations were summarized.

Results

Seven of the 399 patients classified as MHS had histological characteristics consistent with central core disease, and one patient was a carrier of Duchenne’s muscular dystrophy. Eighty-six (22%) patients had histological abnormalities, and five (6%) of these had evidence of “frank” myopathy. No histologic abnormalities were consistent among the MHS patients; however, a higher proportion of MH probands had abnormal histomorphology compared with the general MHS population, and patients with evidence of “frank” myopathy showed similarities in clinical history, biochemistry, CHCT, and genetic testing.

Conclusion

Despite the inability of the histomorphological examination to identify consistent features in MHS patients, histology may serve as a potential adjunct to CHCT and aid in the identification of other myopathies. Nevertheless, the specifics of its utility ought to be assessed in other studies and by way of formal cost-effectiveness analysis.
Literature
1.
go back to reference Denborough MA, Lovell RR. Anaesthetic deaths in a family. Lancet 1960; 2: 45.CrossRef Denborough MA, Lovell RR. Anaesthetic deaths in a family. Lancet 1960; 2: 45.CrossRef
2.
go back to reference Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology 2009; 110: 89-94.PubMedCrossRef Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Trends and outcomes of malignant hyperthermia in the United States, 2000 to 2005. Anesthesiology 2009; 110: 89-94.PubMedCrossRef
3.
go back to reference Rosenbaum HK, Miller JD. Malignant hyperthermia and myotonic disorders. Anesthesiol Clin North America 2002; 20: 623-64.PubMedCrossRef Rosenbaum HK, Miller JD. Malignant hyperthermia and myotonic disorders. Anesthesiol Clin North America 2002; 20: 623-64.PubMedCrossRef
4.
5.
go back to reference Reske-Nielsen E, Haase J, Kelstrup J. Malignant hyperthermia in a family. The neurophysiological and light microscopical study of muscle biopsies of healthy members. Acta Pathol Microbiol Scand A 1975; 83: 645-50. Reske-Nielsen E, Haase J, Kelstrup J. Malignant hyperthermia in a family. The neurophysiological and light microscopical study of muscle biopsies of healthy members. Acta Pathol Microbiol Scand A 1975; 83: 645-50.
6.
go back to reference Gullotta F, Spiess-Kiefer C. Muscle biopsy studies in malignant hyperthermia (German). Anasth Intensivther Notfallmed 1983; 18: 21-7.PubMedCrossRef Gullotta F, Spiess-Kiefer C. Muscle biopsy studies in malignant hyperthermia (German). Anasth Intensivther Notfallmed 1983; 18: 21-7.PubMedCrossRef
7.
go back to reference Mezin P, Payen JF, Bosson JL, Brambilla E, Stieglitz P. Histological support for the difference between malignant hyperthermia susceptible (MHS), equivocal (MHE) and negative (MHN) muscle biopsies. Br J Anaesth 1997; 79: 327-31.PubMedCrossRef Mezin P, Payen JF, Bosson JL, Brambilla E, Stieglitz P. Histological support for the difference between malignant hyperthermia susceptible (MHS), equivocal (MHE) and negative (MHN) muscle biopsies. Br J Anaesth 1997; 79: 327-31.PubMedCrossRef
8.
go back to reference Ranklev E, Henriksson KG, Fletcher R, Germundsson K, Oldfors A, Kalimo H. Clinical and muscle biopsy findings in malignant hyperthermia susceptibility. Acta Neurol Scand 1986; 74: 452-9.PubMedCrossRef Ranklev E, Henriksson KG, Fletcher R, Germundsson K, Oldfors A, Kalimo H. Clinical and muscle biopsy findings in malignant hyperthermia susceptibility. Acta Neurol Scand 1986; 74: 452-9.PubMedCrossRef
9.
go back to reference Figarella-Branger D, Kozak-Ribbens G, Rodet L, et al. Pathological findings in 165 patients explored for malignant hyperthermia susceptibility. Neuromuscul Disord 1993; 3: 553-6.PubMedCrossRef Figarella-Branger D, Kozak-Ribbens G, Rodet L, et al. Pathological findings in 165 patients explored for malignant hyperthermia susceptibility. Neuromuscul Disord 1993; 3: 553-6.PubMedCrossRef
10.
go back to reference Heiman-Patterson T, Fletcher JE, Rosenberg H, Tahmoush AJ. No relationship between fiber type and halothane contracture test results in malignant hyperthermia. Anesthesiology 1987; 67: 82-4.PubMedCrossRef Heiman-Patterson T, Fletcher JE, Rosenberg H, Tahmoush AJ. No relationship between fiber type and halothane contracture test results in malignant hyperthermia. Anesthesiology 1987; 67: 82-4.PubMedCrossRef
11.
go back to reference von Breunig F, Wappler F, Hagel C, et al. Histomorphologic examination of skeletal muscle preparations does not differentiate between malignant hyperthermia-susceptible and -normal patients. Anesthesiology 2004; 100: 789-94.CrossRef von Breunig F, Wappler F, Hagel C, et al. Histomorphologic examination of skeletal muscle preparations does not differentiate between malignant hyperthermia-susceptible and -normal patients. Anesthesiology 2004; 100: 789-94.CrossRef
12.
go back to reference Larach MG. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth Analg 1989; 69: 511-5.PubMedCrossRef Larach MG. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth Analg 1989; 69: 511-5.PubMedCrossRef
13.
go back to reference Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-9.PubMedCrossRef Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-9.PubMedCrossRef
15.
go back to reference Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.PubMedCrossRef Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.PubMedCrossRef
16.
go back to reference Kraev N, Loke JC, Kraev A, MacLennan DH. Protocol for the sequence analysis of ryanodine receptor subtype 1 gene transcripts from human leukocytes. Anesthesiology 2003; 99: 289-96.PubMedCrossRef Kraev N, Loke JC, Kraev A, MacLennan DH. Protocol for the sequence analysis of ryanodine receptor subtype 1 gene transcripts from human leukocytes. Anesthesiology 2003; 99: 289-96.PubMedCrossRef
17.
go back to reference Kraeva N, Riazi S, Loke J, et al. Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population. Can J Anesth 2011; 58: 504-13.PubMedCrossRef Kraeva N, Riazi S, Loke J, et al. Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population. Can J Anesth 2011; 58: 504-13.PubMedCrossRef
18.
go back to reference Brandom BW, Bina S, Wong CA, et al. Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States. Anesth Analg 2013; 116: 1078-86.PubMedCrossRef Brandom BW, Bina S, Wong CA, et al. Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States. Anesth Analg 2013; 116: 1078-86.PubMedCrossRef
19.
go back to reference Sambuughin N, Holley H, Muldoon S, et al. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the North American population. Anesthesiology 2005; 102: 515-21.PubMedCrossRef Sambuughin N, Holley H, Muldoon S, et al. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the North American population. Anesthesiology 2005; 102: 515-21.PubMedCrossRef
20.
go back to reference Engel WK. Selective and nonselective susceptibility of muscle fiber types. A new approach to human neuromuscular diseases. Arch Neurol 1970; 22: 97-117.PubMedCrossRef Engel WK. Selective and nonselective susceptibility of muscle fiber types. A new approach to human neuromuscular diseases. Arch Neurol 1970; 22: 97-117.PubMedCrossRef
21.
go back to reference Kanda F, Okuda S, Matsushita T, Takatani K, Kimura KI, Chihara K. Steroid myopathy: pathogenesis and effects of growth hormone and insulin-like growth factor-I administration. Horm Res 2001; 56(Suppl 1): 24-8.PubMedCrossRef Kanda F, Okuda S, Matsushita T, Takatani K, Kimura KI, Chihara K. Steroid myopathy: pathogenesis and effects of growth hormone and insulin-like growth factor-I administration. Horm Res 2001; 56(Suppl 1): 24-8.PubMedCrossRef
22.
go back to reference Ellis FR. Malignant hyperthermia. In: Ellis FR (Ed.). Inherited Disease and Anaesthesia Elsevier/North-Holland Biomedical Press; 1981: 163-211. Ellis FR. Malignant hyperthermia. In: Ellis FR (Ed.). Inherited Disease and Anaesthesia Elsevier/North-Holland Biomedical Press; 1981: 163-211.
23.
go back to reference Carpenter S, Karpati G. Pathology of skeletal muscle, 2nd ed. Oxford University Press; 2001. Carpenter S, Karpati G. Pathology of skeletal muscle, 2nd ed. Oxford University Press; 2001.
24.
go back to reference Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 2006; 27: 977-89.PubMedCrossRef Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 2006; 27: 977-89.PubMedCrossRef
25.
go back to reference Lu Q, Qiu X, Hu N, Wen H, Su Y, Richardson BC. Epigenetics, disease, and therapeutic interventions. Ageing Res Rev 2006; 5: 449-67.PubMedCrossRef Lu Q, Qiu X, Hu N, Wen H, Su Y, Richardson BC. Epigenetics, disease, and therapeutic interventions. Ageing Res Rev 2006; 5: 449-67.PubMedCrossRef
26.
go back to reference Robinson R, Hopkins P, Carsana A, et al. Several interacting genes influence the malignant hyperthermia phenotype. Hum Genet 2003; 112: 217-8.PubMed Robinson R, Hopkins P, Carsana A, et al. Several interacting genes influence the malignant hyperthermia phenotype. Hum Genet 2003; 112: 217-8.PubMed
27.
go back to reference Harriman DG, Sumner DW, Ellis FR. Malignant hyperpyrexia myopathy. Q J Med 1973; 42: 639-64.PubMed Harriman DG, Sumner DW, Ellis FR. Malignant hyperpyrexia myopathy. Q J Med 1973; 42: 639-64.PubMed
28.
go back to reference Harriman DG. Preanesthetic investigation of malignant hyperthermia: microscopy. Int Anesthesiol Clin 1979; 17: 97-117.PubMedCrossRef Harriman DG. Preanesthetic investigation of malignant hyperthermia: microscopy. Int Anesthesiol Clin 1979; 17: 97-117.PubMedCrossRef
29.
go back to reference Rosenberg H, Antognini JF, Muldoon S. Testing for malignant hyperthermia. Anesthesiology 2002; 96: 232-7.PubMedCrossRef Rosenberg H, Antognini JF, Muldoon S. Testing for malignant hyperthermia. Anesthesiology 2002; 96: 232-7.PubMedCrossRef
30.
go back to reference Miller FW. New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. Ann Rheum Dis 2012; 71(Suppl 2): i82-5.PubMedCrossRef Miller FW. New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. Ann Rheum Dis 2012; 71(Suppl 2): i82-5.PubMedCrossRef
Metadata
Title
Analysis of histomorphology in malignant hyperthermia-susceptible patients
Authors
David Orlov, MD
Julia Keith, MD
Derek Rosen, MD
Sidney Croul, MD
Natalia Kraeva, PhD
Sheila Riazi, MD
Publication date
01-10-2013
Publisher
Springer US
Published in
Canadian Journal of Anesthesia/Journal canadien d'anesthésie / Issue 10/2013
Print ISSN: 0832-610X
Electronic ISSN: 1496-8975
DOI
https://doi.org/10.1007/s12630-013-0005-9

Other articles of this Issue 10/2013

Canadian Journal of Anesthesia/Journal canadien d'anesthésie 10/2013 Go to the issue